RxDoctor Payments DataLook up a doctor →

Cynthia Levy, MD

Hepatology · Miami, FLNPI 1215979901

Payments from drug & device makers

$1,700,238in general payments, 2019–2025

Across 665 payments — averaging $2556.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$354K
  • Mitsubishi Tanabe Pharma Development America, Inc.$310K
  • GSK$286K
  • Intercept Pharmaceuticals, Inc.$224K
  • Tanabe Pharma America, Inc.$191K
  • Ipsen Bioscience Inc.$110K
  • plus $227K from 15 others
$1,537in research payments, 2019–2025

Across 9 payments — averaging $170.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$2K

What the payments were for

  • Consulting fees$67,13776%
  • Speaking & faculty fees$18,60521%
  • Travel & lodging$1,1151%
  • Food & beverage$1,2521%
  • Education$1930%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$37,736
Medicare patients
223
Services billed
355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid46$510,130
XifaxanRifaximin66$208,753
VemlidyTenofovir Alafenamide32$43,684
Ursodiol194$41,231
LinzessLinaclotide30$20,623
Sirolimus15$7,054
Entecavir33$6,634
Tacrolimus16$6,214
Butorphanol Tartrate15$5,572
Mycophenolate Mofetil32$4,084
Tenofovir Disoproxil Fumarate17$3,279
Azathioprine38$1,973
Omeprazole72$1,285
Lactulose32$1,059
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl58$763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$224,000$510,13046 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$3,618$208,75366 claims
GileadVemlidy$353,540$43,68432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other hepatology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →